An initial clinical study on the efficacy of cisplatin-releasing gelatin microspheres for metastatic liver tumors.
OBJECTIVE
To evaluate the antitumor effect and side effects of cisplatin-releasing gelatin microspheres (Cis-GMSs) for metastatic liver tumors.


METHODS
Cis-GMSs that degraded over 14 days were employed. The subjects comprised a total of nine cases. Transcatheter hepatic artery embolization (TAE) using Cis-GMSs (Cis-GMSs-TAE) was performed 13 times in total. Six cases, each containing one to five tumors in a single segment to an entire lobe were treated by Cis-GMSs-TAE. In the remaining three cases with six or more metastatic liver tumors, the right and left lobes were treated by Cis-GMSs-TAE at a 2-week interval.


RESULTS
There were two complete response (CR), one partial response (PR) and six stable disease (SD) cases. The response rate was 33.3%. The average rate of reduction in tumor diameter was 32%. Disappearance of metastatic liver tumors was observed in only two of the nine cases. As for side effects and complications, post-embolization syndrome was observed in eight cases, but no severe complications such as cholangitis or liver abscess were observed.


CONCLUSIONS
Considering the mild side effects by Cis-GMSs-TAE, it is suggested that Cis-GMSs-TAE should be tried at least once as topical therapy for metastatic liver tumors when the response to systemic chemotherapy and other treatments is not satisfactory.
Nitta
Norihisa
N
Department of Radiology, Shiga University of Medical Science, Seta, Tsukinowa-cho, Otsu, Shiga 520-2192, Japan. r34nitta@yahoo.co.jp
Ohta
Shinichi
S
Tanaka
Toyohiko
T
Takazakura
Ryutaro
R
Toyama
Tetsuya
T
Sonoda
Akinaga
A
Seko
Ayumi
A
Furukawa
Akira
A
Takahashi
Masashi
M
Murata
Kiyoshi
K
Kurumi
Yoshimasa
Y
Tani
Toru
T
Sakamoto
Tsutomu
T
Tabata
Yasuhiko
Y
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage* / Q000737:chemistry; D003692:Delayed-Action Preparations / Q000008:administration & dosage* / Q000737:chemistry; D005260:Female; D005780:Gelatin / Q000737:chemistry; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary*; D008297:Male; D008863:Microspheres; D008875:Middle Aged; D010865:Pilot Projects; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D005780:Gelatin; D002945:Cisplatin